Ristocetin: A Means of Differentiating Von Willebrand’s Disease Into Two Groups

作者：Margaret A. Howard, R. J. Sawers, B. G. Firkin · 发表于：Blood · 年份：1973 · DOI：10.1182/blood.v41.5.687.687 · 被引用次数：146 · 研究领域：Platelet Disorders and Treatments、Antiplatelet Therapy and Cardiovascular Diseases、Myeloproliferative Neoplasms: Diagnosis and Treatment

Abstract Earlier studies have shown that patients with von Willebrand’s disease are considered to have normal platelets, but they lack at least one plasma protein. Results are presented indicating that ristocetin, known to aggregate normal platelets, fails to cause platelet aggregation in the group of von Willebrand’s disease patients exhibiting no platelet adhesiveness. It is postulated that there may be two groups of patients within von Willebrand’s disease and, further, that ristocetin will provide a useful approach to study the plasma deficiency or abnormality in von Willebrand’s disease.